FDA Issues 510(k)/Substantial Equivalence Draft Guidance Describes Benefit-Risk Factors Considered for New 510(k) Devices with Different Technical Characteristics


On July 15, 2014, the U.S. Food and Drug Administration (FDA) issued a Draft Guidance document titled Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications [510(k)]with Different Technological Characteristics (“Draft Guidance”). The Draft Guidance focuses on the benefit-risk factors FDA uses to determine whether a new 510(k) device with different technological characteristics that do not raise different questions of safety and effectiveness is as safe and effective as a predicate device. The Draft Guidance does not address factors for determining whether the new and predicate devices have the same intended use or whether the different technological characteristics raise different questions of safety and effectiveness. Comments on the Draft Guidance are due by October 14, 2014 and should reference docket number FDA–2014–D–0900.

Weighing the Risks and Benefits

Broadly, the Draft Guidance notes that FDA considers each risk or benefit factor in comparison to the predicate device. Additionally, FDA reviews each relevant factor both individually and in the aggregate. A finding of decreased benefit or increased risk, as compared to the predicate device, will not necessarily result in a not substantially equivalent (“NSE”) determination. Rather, FDA will balance the benefits and risks and may still reach a substantial equivalence (“SE”) determination.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Written by:


King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.